Conventional blood tests miss what’s happening inside coronary arteries. PlaqueTec reckons it’s found a way to look directly at the problem.
The Cambridge-based medtech firm closed a $5 million funding round this week, oversubscribed and backed entirely by existing shareholders—a vote of confidence that speaks louder than any pitch deck. The capital will accelerate development of BioCarta™, PlaqueTec’s cardiovascular disease data platform built on intracoronary liquid biopsy technology.
What sets the approach apart is where it samples. Instead of analysing blood drawn from an arm, PlaqueTec’s technology assesses proteomic biomarkers at the actual site of coronary plaque formation. The distinction matters: systemic blood tests capture a diluted snapshot of what’s circulating throughout the body, while intracoronary sampling reveals the molecular signals unfolding precisely where arterial disease develops.
Data emerging from the company’s ongoing BIOPATTERN clinical trial has already begun identifying novel inflammatory drivers across different patient subgroups. That granularity—the ability to see which inflammatory pathways are active in which patients—positions BioCarta as a differentiation tool for therapeutic development and precision medicine approaches to cardiovascular disease.
For a sector historically dominated by one-size-fits-all interventions, the implications are significant.
Burges Salmon’s Corporate and M&A team advised on the transaction, led by senior associate Katie Carter alongside partner Alex Lloyd and solicitor Sophie Dicks. The independent UK law firm guided PlaqueTec through a fundraise that, unusually, saw no new investors join the cap table—existing backers chose to deepen their stakes rather than dilute their positions.
“PlaqueTec is building a genuinely differentiated data asset at the intersection of cardiovascular research, clinical insight and therapeutic development,” Carter noted. “This successful fundraise is a strong endorsement of both the company’s technology and its long-term strategy. We’re pleased to have supported PlaqueTec on this important milestone and look forward to seeing the BioCarta platform continue to gain momentum.”
The company is positioning BioCarta not just as a diagnostic tool but as a partnership and licensing asset. Cardiovascular disease remains the leading cause of death globally, yet therapeutic development has struggled with patient stratification—determining which treatments work for which individuals. Proteomic data captured at the disease site could inform that stratification with far greater precision than current methods allow.
Mark Ebner, PlaqueTec’s Head of Finance, emphasised the shareholder confidence underpinning the round. “This successful raise underlines the confidence our shareholders have in PlaqueTec’s data-led approach to cardiovascular disease and the long-term potential of the BioCarta platform,” he said. “We’re grateful to Alex, Katie, Sophie and the Burges Salmon team for their outstanding support, sector insight and clear, commercial advice throughout the transaction.”
The liquid biopsy space has seen significant investment in oncology over the past five years, with companies like Guardant Health and Grail raising hundreds of millions to detect cancer biomarkers in blood. Cardiovascular applications have lagged behind, partly because circulating biomarkers for heart disease are less well characterised and partly because accessing the coronary environment requires invasive procedures performed during cardiac catheterisation.
PlaqueTec’s approach threads that needle by piggybacking on existing interventional cardiology procedures. When patients undergo angiography or stenting, the company’s technology can capture intracoronary samples without adding meaningful procedural risk or time. That practicality matters for clinical adoption.
BioCarta’s growing repository of proteomic and clinical data represents what the company describes as a unique asset. As the dataset expands through BIOPATTERN and potential future trials, the platform’s value proposition strengthens—more patients, more plaque types, more inflammatory profiles mapped against clinical outcomes.
Whether pharmaceutical companies and diagnostics firms will pay to access that data, or partner to develop targeted therapies based on it, remains the commercial question. But existing shareholders have placed their bet. By writing cheques to fill an oversubscribed round, they’ve signalled belief that the market for precision cardiovascular diagnostics is not only real but underserved.
For PlaqueTec, the capital buys runway to deepen the dataset, refine the technology and pursue partnerships. The next milestone will likely involve demonstrating that the inflammatory drivers identified through BioCarta can predict clinical outcomes or guide treatment decisions—proof that looking directly at diseased arteries reveals something actionable, not just interesting.
Burges Salmon, with offices across Bristol, Edinburgh and London, has advised on a string of life sciences transactions as the UK medtech sector attracts sustained venture and strategic interest. The firm operates as an independent, competing with Magic Circle and US firms on complex corporate work while maintaining a partner-led model.
The timing of PlaqueTec’s fundraise coincides with broader momentum in precision medicine, where payers and regulators increasingly demand evidence that diagnostics inform treatment decisions rather than simply generating data. BioCarta’s structure—linking proteomic profiles to patient outcomes—aligns with that shift.
What happens next depends on the clinical trial results and whether PlaqueTec can translate molecular insights into partnerships that accelerate therapeutic development. The $5 million provides the resources to find out. The oversubscription suggests existing backers believe the answer will be yes.
